AIM Vaccine Co., Ltd. (HKG:6660)
Hong Kong · Delayed Price · Currency is HKD 1.590
-0.050 (-3.05%)
Jul 10, 2026, 10:45 AM HKT
AIM Vaccine Revenue
In the year 2025, AIM Vaccine had annual revenue of 1.17B CNY, down -9.29%. AIM Vaccine had revenue of 651.02M in the half year ending December 31, 2025, with 0.62% growth.
Revenue
1.17B CNY
Revenue Growth
-9.29%
P/S Ratio
1.55
Revenue / Employee
795.14K CNY
Employees
1,466
Market Cap
2.01B HKD
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.17B | -119.36M | -9.29% |
| Dec 31, 2024 | 1.29B | 97.56M | 8.22% |
| Dec 31, 2023 | 1.19B | -76.61M | -6.06% |
| Dec 31, 2022 | 1.26B | -306.06M | -19.49% |
| Dec 31, 2021 | 1.57B | -67.84M | -4.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 2.00B |
| Viva Biotech Holdings | 1.92B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.45B |
| Mabpharm | 718.98M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 171.70M |
| HJ Science | 14.54M |
| SinoMab BioScience | 6.28M |
| Clover Biopharmaceuticals | 3.90M |